» Articles » PMID: 28416672

Bisulfite-converted Duplexes for the Strand-specific Detection and Quantification of Rare Mutations

Overview
Specialty Science
Date 2017 Apr 19
PMID 28416672
Citations 9
Authors
Affiliations
Soon will be listed here.
Abstract

The identification of mutations that are present at low frequencies in clinical samples is an essential component of precision medicine. The development of molecular barcoding for next-generation sequencing has greatly enhanced the sensitivity of detecting such mutations by massively parallel sequencing. However, further improvements in specificity would be useful for a variety of applications. We herein describe a technology (BiSeqS) that can increase the specificity of sequencing by at least two orders of magnitude over and above that achieved with molecular barcoding and can be applied to any massively parallel sequencing instrument. BiSeqS employs bisulfite treatment to distinguish the two strands of molecularly barcoded DNA; its specificity arises from the requirement for the same mutation to be identified in both strands. Because no library preparation is required, the technology permits very efficient use of the template DNA as well as sequence reads, which are nearly all confined to the amplicons of interest. Such efficiency is critical for clinical samples, such as plasma, in which only tiny amounts of DNA are often available. We show here that BiSeqS can be applied to evaluate transversions, as well as small insertions or deletions, and can reliably detect one mutation among >10,000 wild-type molecules.

Citing Articles

The Origin of Highly Elevated Cell-Free DNA in Healthy Individuals and Patients with Pancreatic, Colorectal, Lung, or Ovarian Cancer.

Mattox A, Douville C, Wang Y, Popoli M, Ptak J, Silliman N Cancer Discov. 2023; 13(10):2166-2179.

PMID: 37565753 PMC: 10592331. DOI: 10.1158/2159-8290.CD-21-1252.


Circulating tumor DNA: current challenges for clinical utility.

Dang D, Park B J Clin Invest. 2022; 132(12).

PMID: 35703177 PMC: 9197509. DOI: 10.1172/JCI154941.


A new approach to decode DNA methylome and genomic variants simultaneously from double strand bisulfite sequencing.

Liang J, Zhang K, Yang J, Li X, Li Q, Wang Y Brief Bioinform. 2021; 22(6).

PMID: 34058751 PMC: 8575003. DOI: 10.1093/bib/bbab201.


Tumor DNA as a Cancer Biomarker through the Lens of Colorectal Neoplasia.

Cohen J, Diergaarde B, Papadopoulos N, Kinzler K, Schoen R Cancer Epidemiol Biomarkers Prev. 2020; 29(12):2441-2453.

PMID: 33033144 PMC: 7710619. DOI: 10.1158/1055-9965.EPI-20-0549.


Next-Generation Genotoxicology: Using Modern Sequencing Technologies to Assess Somatic Mutagenesis and Cancer Risk.

Salk J, Kennedy S Environ Mol Mutagen. 2019; 61(1):135-151.

PMID: 31595553 PMC: 7003768. DOI: 10.1002/em.22342.


References
1.
Wang Y, Sundfeldt K, Mateoiu C, Shih I, Kurman R, Schaefer J . Diagnostic potential of tumor DNA from ovarian cyst fluid. Elife. 2016; 5. PMC: 4946896. DOI: 10.7554/eLife.15175. View

2.
Springer S, Wang Y, Dal Molin M, Masica D, Jiao Y, Kinde I . A combination of molecular markers and clinical features improve the classification of pancreatic cysts. Gastroenterology. 2015; 149(6):1501-10. PMC: 4782782. DOI: 10.1053/j.gastro.2015.07.041. View

3.
Wang Y, Springer S, Mulvey C, Silliman N, Schaefer J, Sausen M . Detection of somatic mutations and HPV in the saliva and plasma of patients with head and neck squamous cell carcinomas. Sci Transl Med. 2015; 7(293):293ra104. PMC: 4587492. DOI: 10.1126/scitranslmed.aaa8507. View

4.
Kinde I, Bettegowda C, Wang Y, Wu J, Agrawal N, Shih I . Evaluation of DNA from the Papanicolaou test to detect ovarian and endometrial cancers. Sci Transl Med. 2013; 5(167):167ra4. PMC: 3757513. DOI: 10.1126/scitranslmed.3004952. View

5.
Garraway L, Lander E . Lessons from the cancer genome. Cell. 2013; 153(1):17-37. DOI: 10.1016/j.cell.2013.03.002. View